Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on pradaxa (Dabigatran)

Spine

Volumn 37, Issue 14, 2012, Pages E863-E865

  Truumees, Eeric ^a   Gaudu, Tracy ^a   Dieterichs, Chad ^a   Geck, Matthew ^a   Stokes, John ^a  

^a Seton Brain and Spine Institute   (United States)

Author keywords

Complications of spine surgery; Dabigatran etexilate; Direct thrombin inhibitor; Epidural hematoma.; Oral anticoagulant

Indexed keywords

ALBUMIN; DABIGATRAN ETEXILATE; FRESH FROZEN PLASMA; GELATIN SPONGE; GELFOAM; NOVOSEVEN RT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADDUCTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BABINSKI REFLEX; BLADDER FUNCTION; CASE REPORT; CAUTERIZATION; CLINICAL ARTICLE; COMPRESSION FRACTURE; EPIDURAL HEMATOMA; ERYTHROCYTE TRANSFUSION; HEMOSTASIS; HIP; HUMAN; INSTRUMENTED POSTERIOR SPINAL FUSION; INTESTINE FUNCTION; LOW BACK PAIN; LOWER LIMB; MALE; MEDICAL HISTORY; OPEN FRACTURE REDUCTION; OPERATIVE BLOOD LOSS; OSTEOSYNTHESIS; PARESTHESIA; PERONEUS MUSCLE; POSTERIOR SPINE FUSION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REHABILITATION CENTER; RETROSPECTIVE STUDY; SPINAL CORD COMPRESSION; SPINAL CORD DECOMPRESSION; SURGICAL INTENSIVE CARE UNIT; THORACIC SPINE; THROMBOCYTE TRANSFUSION; TIBIALIS ANTERIOR MUSCLE; TRANSPEDICULAR DECOMPRESSION; BLEEDING; BLOOD TRANSFUSION; DECOMPRESSION SURGERY; INJURY; INTRAOPERATIVE PERIOD; SPINE FRACTURE; SPINE FUSION; TREATMENT OUTCOME; VERTEBRA;

AGED; ANTICOAGULANTS; BENZIMIDAZOLES; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; DECOMPRESSION, SURGICAL; HEMATOMA, EPIDURAL, CRANIAL; HUMANS; INTRAOPERATIVE PERIOD; MALE; PYRIDINES; RETROSPECTIVE STUDIES; SPINAL FRACTURES; SPINAL FUSION; THORACIC VERTEBRAE; TREATMENT OUTCOME;

EID: 84856936368     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e31824ee320     Document Type: Article

References (20)

1. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15 ( suppl 1 ): 9S-16S.
2. Baetz BE, Spinler SA. Dabigatran etexilate: An oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008; 28 : 1354-73.
3. Hrebickova L, Nawarskas JJ, Anderson JR. Ximelagatran: A new oral anticoagulant. Heart Dis 2003; 5 : 397-408.
4. Dabigatran etexilate (Pradaxa)-A new oral anticoagulant. Med Lett Drugs Ther 2010; 52 : 89-90.
5. Sanford M, Plosker GL. Dabigatran etexilate. Drugs 2008; 68 : 1699-1709.
6. Menzin J, Boulanger L, Hauch O, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fi brillation in clinic settings: A multi-site managed-care study. Ann Pharmacother 2005; 39 : 446-51.
7. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fi brillation. N Engl J Med 2009; 361 : 1139-51.
8. Pradaxa [package insert]. Ridgefi eld, CT : Boehringer Ingelheim Pharmaceuticals, Inc.; 2010.
9. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fi brillation (PETRO Study). Am J Cardiol 2007; 100 : 1419-26.
10. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64 : 292-303.
11. Ma TK, Yan BP, Lam YY. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. Pharmacol Ther 2011; 129 : 185-94.
12. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103 : 1116-27.
13. Dabigatran: new drug. Continue to use heparin, a better-known option. Prescrire Int 2009; 18 : 97-9.
14. MA C. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost 2009; 7 ( suppl 1 ): 107-10.
15. Eerenberg ES, Sijpkens MK, Kamphuisen PW, et al. Prothrombin complex concentrate reverses the anticoagulant effect of Rivaroxaban in healthy volunteers. ASH Annual Meeting, December 4-7, 2010. Vol abstract 1094. Orlando, FL, 2010.
16. Morishima Y, Honda Y, Shibano T. Anti-Inhibitor Coagulant Complex, Prothrombin Complex Concentrate, and recombinant factor VIIa reverse prothrombin time prolonged by Edoxaban in human plasma. ASH Annual Meeting, December 4-7, 2010. Vol abstract 3319. Orlando, FL, 2010.
17. Mariani G, Dolce A, Batorova A, et al. Recombinant, activated factor VII for surgery in factor VII defi ciency: A prospective evaluation-The surgical STER. Br J Haematol 2011; 152 : 340-6.
18. Valentino LA, Cooper DL, Goldstein B. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia 2011; 17 : 579-89.
19. Hedner U, Lee CA. First 20 years with recombinant FVIIa (NovoSeven). Haemophilia 2011; 17 : e172-82.
20. Ganetsky M, Babu K, Salhanick S, et al. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 2011; 7 : 281-7.